Nephrotoxicity of iodixanol versus iopamidol in patients with acute coronary syndrome
Objectives: The iso-osmolar contrast agent iodixanol may be associated with fewer contrast-induced acute kidney injuries when compared with low-osmolar contrast agents. The aim of this study is to compare iodixanol and iopamidol in patients with acute coronary syndrome (ACS) who are currently under...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KARE Publishing
2013-02-01
|
| Series: | Türk Kardiyoloji Derneği Arşivi |
| Subjects: | |
| Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-81504 |
| _version_ | 1797917827895656448 |
|---|---|
| author | Mehmet Gül Burak Turan Murat Uğur Ayça Türer Uğur Fındıkçıoğlu Mehmet Ergelen Hüseyin Uyarel |
| author_facet | Mehmet Gül Burak Turan Murat Uğur Ayça Türer Uğur Fındıkçıoğlu Mehmet Ergelen Hüseyin Uyarel |
| author_sort | Mehmet Gül |
| collection | DOAJ |
| description | Objectives: The iso-osmolar contrast agent iodixanol may be associated with fewer contrast-induced acute kidney injuries when compared with low-osmolar contrast agents. The aim of this study is to compare iodixanol and iopamidol in patients with acute coronary syndrome (ACS) who are currently undergoing coronary angiography. Study design: Two hundred and seventy five consecutive patients who presented to a tertiary cardiovascular center with acute non-ST elevation myocardial infarction and underwent coronary angiography as a part of an early invasive strategy were included in the study (mean age 58+-11 years, 79% male). Study participants were administered either iodixanol (n=45) or iopamidol (n=230) and the groups were compared for the highest creatinine levels, the absolute and percent change in creatinine levels, and for the development of contrast induced nephropathy within 72 hours of the procedure. Results: Baseline demographic and clinical characteristics of the patients were similar between the two groups. There were no differences in the preprocedural serum creatinine (iopamidol 1.10+-0.54 mg/dl, iodixanol 1.09+-0.24 mg/dl, p=0.680), glomerular filtration rate (iopamidol 89+-35 ml/dk/1.73 m2, iodixanol 89+-26 ml/dk/1.73 m2, p=0.934), or contrast volume used during the procedure (iopamidol 180+-80 ml vs. iodixanol 166+-73 ml, p=0.226) between the groups. The absolute change in serum creatinine after the procedure (iopamidol 0.136+-0.346 mg/dl, iodixanol 0.072+-0.070 mg/dl, p=0.118) and the percent change in serum creatinine after the procedure (iopamidol 12.1+-29.6%, iodixanol 6.8+-6.9%, p=0.075) were not statistically significant between the two groups. Contrast induced nephropathy developed 10% (95% confidence interval [CI] 6–14%) in iopamidol group whereas it was 2.2% (95% CI -2-7%) in iodixanol group (p=0.144). Conclusion: Iodixanol was not superior to iopamidol regarding contrast induced acute kidney injury after coronary angiography in an unselected general patient population with ACS. |
| first_indexed | 2024-04-10T13:20:42Z |
| format | Article |
| id | doaj.art-d35814d6c1224d10acafd0fc646eeaa6 |
| institution | Directory Open Access Journal |
| issn | 1016-5169 |
| language | English |
| last_indexed | 2024-04-10T13:20:42Z |
| publishDate | 2013-02-01 |
| publisher | KARE Publishing |
| record_format | Article |
| series | Türk Kardiyoloji Derneği Arşivi |
| spelling | doaj.art-d35814d6c1224d10acafd0fc646eeaa62023-02-15T16:12:05ZengKARE PublishingTürk Kardiyoloji Derneği Arşivi1016-51692013-02-01411212710.5543/tkda.2013.81504TKDA-81504Nephrotoxicity of iodixanol versus iopamidol in patients with acute coronary syndromeMehmet Gül0Burak Turan1Murat Uğur2Ayça Türer3Uğur Fındıkçıoğlu4Mehmet Ergelen5Hüseyin Uyarel6Department Of Cardiology, Mehmet Akif Ersoy Training And Research Hospital, İstanbul, TurkeyDepartment Of Cardiology, Derince Training And Research Hospital, Kocaeli, TurkeyDepartment Of Cardiology, Derince Training And Research Hospital, Kocaeli, TurkeyDepartment Of Cardiology, İzmit Seka State Hospital, Kocaeli, TurkeyDepartment Of Cardiology, Dr. Lütfü Kırdar Kartal Training And Research Hospital, İstanbul, TurkeyDepartment Of Cardiology, Bezmialem Vakıf University, İstanbul, TurkeyDepartment Of Cardiology, Bezmialem Vakıf University, İstanbul, TurkeyObjectives: The iso-osmolar contrast agent iodixanol may be associated with fewer contrast-induced acute kidney injuries when compared with low-osmolar contrast agents. The aim of this study is to compare iodixanol and iopamidol in patients with acute coronary syndrome (ACS) who are currently undergoing coronary angiography. Study design: Two hundred and seventy five consecutive patients who presented to a tertiary cardiovascular center with acute non-ST elevation myocardial infarction and underwent coronary angiography as a part of an early invasive strategy were included in the study (mean age 58+-11 years, 79% male). Study participants were administered either iodixanol (n=45) or iopamidol (n=230) and the groups were compared for the highest creatinine levels, the absolute and percent change in creatinine levels, and for the development of contrast induced nephropathy within 72 hours of the procedure. Results: Baseline demographic and clinical characteristics of the patients were similar between the two groups. There were no differences in the preprocedural serum creatinine (iopamidol 1.10+-0.54 mg/dl, iodixanol 1.09+-0.24 mg/dl, p=0.680), glomerular filtration rate (iopamidol 89+-35 ml/dk/1.73 m2, iodixanol 89+-26 ml/dk/1.73 m2, p=0.934), or contrast volume used during the procedure (iopamidol 180+-80 ml vs. iodixanol 166+-73 ml, p=0.226) between the groups. The absolute change in serum creatinine after the procedure (iopamidol 0.136+-0.346 mg/dl, iodixanol 0.072+-0.070 mg/dl, p=0.118) and the percent change in serum creatinine after the procedure (iopamidol 12.1+-29.6%, iodixanol 6.8+-6.9%, p=0.075) were not statistically significant between the two groups. Contrast induced nephropathy developed 10% (95% confidence interval [CI] 6–14%) in iopamidol group whereas it was 2.2% (95% CI -2-7%) in iodixanol group (p=0.144). Conclusion: Iodixanol was not superior to iopamidol regarding contrast induced acute kidney injury after coronary angiography in an unselected general patient population with ACS.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-81504kidney diseases/bloodglomerular filtration rate; injectionsintra-arterial; iodixanol; iopamidol; cardiac catheterization; contrast media/adverse effects; creatinine/blood; percutaneous coronary intervention. |
| spellingShingle | Mehmet Gül Burak Turan Murat Uğur Ayça Türer Uğur Fındıkçıoğlu Mehmet Ergelen Hüseyin Uyarel Nephrotoxicity of iodixanol versus iopamidol in patients with acute coronary syndrome Türk Kardiyoloji Derneği Arşivi kidney diseases/blood glomerular filtration rate; injections intra-arterial; iodixanol; iopamidol; cardiac catheterization; contrast media/adverse effects; creatinine/blood; percutaneous coronary intervention. |
| title | Nephrotoxicity of iodixanol versus iopamidol in patients with acute coronary syndrome |
| title_full | Nephrotoxicity of iodixanol versus iopamidol in patients with acute coronary syndrome |
| title_fullStr | Nephrotoxicity of iodixanol versus iopamidol in patients with acute coronary syndrome |
| title_full_unstemmed | Nephrotoxicity of iodixanol versus iopamidol in patients with acute coronary syndrome |
| title_short | Nephrotoxicity of iodixanol versus iopamidol in patients with acute coronary syndrome |
| title_sort | nephrotoxicity of iodixanol versus iopamidol in patients with acute coronary syndrome |
| topic | kidney diseases/blood glomerular filtration rate; injections intra-arterial; iodixanol; iopamidol; cardiac catheterization; contrast media/adverse effects; creatinine/blood; percutaneous coronary intervention. |
| url | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tkd&un=TKDA-81504 |
| work_keys_str_mv | AT mehmetgul nephrotoxicityofiodixanolversusiopamidolinpatientswithacutecoronarysyndrome AT burakturan nephrotoxicityofiodixanolversusiopamidolinpatientswithacutecoronarysyndrome AT muratugur nephrotoxicityofiodixanolversusiopamidolinpatientswithacutecoronarysyndrome AT aycaturer nephrotoxicityofiodixanolversusiopamidolinpatientswithacutecoronarysyndrome AT ugurfındıkcıoglu nephrotoxicityofiodixanolversusiopamidolinpatientswithacutecoronarysyndrome AT mehmetergelen nephrotoxicityofiodixanolversusiopamidolinpatientswithacutecoronarysyndrome AT huseyinuyarel nephrotoxicityofiodixanolversusiopamidolinpatientswithacutecoronarysyndrome |